Literature DB >> 8204352

Serum concentrations of cytokines in patients with Hodgkin's disease.

J Y Blay1, J P Farcet, A Lavaud, D Radoux, S Chouaïb.   

Abstract

Serum concentrations of interleukin (IL)-1 alpha, IL-2, IL-4, IL-6 and tumour necrosis factor (TNF) were measured in 24 untreated patients with Hodgkin's disease and in 24 healthy volunteers matched for age and sex. Serum levels of IL-1 alpha were significantly higher in patients with Hodgkin's disease. The number of patients with detectable serum IL-2 or IL-6 levels was significantly higher in patients with Hodgkin's disease as compared to the control group. No difference was observed for TNF. IL-4 was undetectable in all patients. Serum cytokine levels were not significantly different in patients with and without systemic "B" symptoms (weight loss or fever and night sweats) in the different histological subtypes and clinical stages. Serum concentrations of IL-1 alpha, IL-2, IL-6 and TNF were not correlated to the erythrocyte sedimentation rate, fibrinogenaemia or thrombocyte number. These results indicate that subsets of patients with Hodgkin's disease have detectable serum IL-1 alpha, IL-2 and IL-6 levels, but that other mediators are likely to be involved in the associated clinical and biological inflammatory syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204352     DOI: 10.1016/0959-8049(94)90249-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Haptoglobin-related protein as a serum marker in malignant lymphoma.

Authors:  R Epelbaum; C Shalitin; R Segal; C Valansi; I Arselan; D Faraggi; M Leviov; M Ben-Shahar; N Haim
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

2.  Prognostic Significance of IL-6 in Hodgkin Lymphoma.

Authors:  Sainath Bhethanabhotla; Akash Tiwari; M C Sharma; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2019-03-04       Impact factor: 1.967

3.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

4.  Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience.

Authors:  S Viviani; P Notti; V Bonfante; P Verderio; P Valagussa; G Bonadonna
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

5.  Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Authors:  S Viviani; E Camerini; V Bonfante; A Santoro; M Balzarotti; M Fornier; L Devizzi; P Verderio; P Valagussa; G Bonadonna
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

6.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

7.  Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis.

Authors:  Xingchun Peng; Jun Shi; Wanqun Sun; Xuzhi Ruan; Yang Guo; Lunhua Zhao; Jue Wang; Bin Li
Journal:  Oncotarget       Date:  2018-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.